BioPharmaceutical.Info
PHARMACEUTICAL AND BIOTECH NEWS
A daily compilation of industry news from
Feuerbach and Associates

More News, Less Hype







The Top Industry News Stories



Translate This Page







Get Stock Quotes



The Blogroll

Alison Bass
Bioethics Forum
BioJobBlog
BioPharma Today
Biotech Blog
Cafe Pharma
Drug and Device Law
Drug Channels
Drugwonks
Eye on FDA
Euro Pharma Today
FDA Matters
In the Pipeline
In Vivo
MedAdNews
PharmaGossip
Pharmalot
Pharma Marketing
The BioBlog (beta)







Medilexicon Medical Term Search
Search By Abbreviation
Search By Definition
Medical Dictionary
Pharma Companies
Associations
medical dictionary search provided by MediLexicon.com



Drugs @FDA Home
Look-Up

(Type in part or all of name)




FDA Orange Book
Approved Drug Products with Therapeutic Equivalence Evaluations

Search by Active Ingredient:
(Type in part or all of name)

Select the list you would like to search:
Prescription Drug
Over-the-Counter
Discontinued Drugs

Search by Proprietary Name:
(Type in part or all of name)

Select the list you would like to search:
Prescription Drug
Over-the-Counter
Discontinued Drugs




Tell Others about Us











Doctors scour drug supplies after fake Avastin found
Thu, 16 Feb 2012 00:40:47 GMT
NEW YORK (Reuters) - A U.S. distributor of phony vials of the widely-used cancer drug Avastin aroused suspicion at doctor's offices as early as July, well before health regulators issued their own warning and sparked new alarm over counterfeit medicines.

Biosante Soars Following Drug Approval From FDA
Thu, 16 Feb 2012 12:51:40 GMT
From Associated Press (February 15, 2012) NEW YORK -- Shares of BioSante Pharmaceuticals Inc. surged Thursday after regulators approved a testosterone gel that will be marketed by its partner Teva Pharmaceutical Industries...

Teva Chief Says Company Prepared in Case of Israel-Iran Conflict
Thu, 16 Feb 2012 12:46:52 GMT
Teva chief says company prepared in case of Israel-Iran conflict [The Philadelphia Inquirer] From Philadelphia Inquirer (PA) (February 16, 2012) Feb. 16--Without actually saying "Iran," Teva Pharmaceutical Industries Ltd's chief executive officer...

French court finds Monsanto guilty of poisoning farmer
Thu, 16 Feb 2012 08:22:59 GMT - NewscastMedia.com
French farmer Paul FranA ois, has won a case against biotech giant Monsanto, in which a judge in France ruled that the companybcould be held liable for poisoning the farmer.

Stock offering nets Exelixis $65 million
Wed, 15 Feb 2012 22:15:43 GMT

Antibiotics no help against most sinus infections
Wed, 15 Feb 2012 21:17:14 GMT
NEW YORK (Reuters Health) - Antibiotics don't help fight most sinus infections, although doctors routinely prescribe them for that purpose, researchers said Tuesday.

Decision time for researchers of deadly bird flu
Wed, 15 Feb 2012 19:23:43 GMT
LONDON/GENEVA (Reuters) - When 22 bird flu experts meet at the World Health Organization this week, they will be tasked with deciding just how far scientists should go in creating lethal mutant viruses in the name of research.

BioCryst hep C drug shows promise, shares jump
Wed, 15 Feb 2012 19:02:04 GMT
(Reuters) - BioCryst Pharmaceuticals Inc said its experimental hepatitis C drug showed promise in preclinical studies, sending its shares up as much as 16 percent to their highest in more than seven months.

American Society of Hematology Statement on Critical Methotrexate Drug Shortage
Wed, 15 Feb 2012 19:02:00 GMT
WASHINGTON, Feb. 15, 2012 /PRNewswire-USNewswire/ -- As the world's largest professional society concerned with the causes and treatment of blood disorders, many of our more than 16,000 members are on the front lines of dealing with the country's severe shortage of methotrexate, a...

Bishops plan big birth-control battle expansion
Wed, 15 Feb 2012 17:17:02 GMT
(Reuters) - Catholic bishops, energized by a battle over contraception funding, are planning an aggressive campaign to rally Americans against a long list of government measures which they say intrude on religious liberty.

How secure are labs handling world's deadliest pathogens?
Wed, 15 Feb 2012 16:53:57 GMT
NEW YORK/CHICAGO (Reuters) - To reach his office in Galveston National Laboratory, where scientists study deadly pathogens such as the Ebola and Marburg viruses, director James Le Duc swipes his key card at the building's single entrance, which is guarded 24/7 by Texas state police.






Opinion, Columns and Blogs

Fakes Infiltrate Injectable Drugs
Thu, 16 Feb 2012 01:03:32 GMT

FDA Issues Holistic Warning To Merck KGgA
Thu, 16 Feb 2012 13:24:13 GMT - Ed Silverman
In what appears to be a calculated review of a supply chain, the FDA last summer inspected three Merck KGgA manufacturing plants in Europe - one that makes active pharmaceutical ingredients, another that makes finished prescription drugs and a third that is responsible for testing meds for the US market - and all three failed the inspections. The details of the assorted manufacturing failures - and there are many details because there were many failures - can be found in a December 15, 2011, warning letter...

Pharmalot... Pharmalittle... Good Morning
Thu, 16 Feb 2012 13:01:50 GMT - Ed Silverman
Hello, everyone, and how are you today? Cloudy skies are hovering over the Pharmalot corporate campus, but our spirits are sunny. You know the mantra from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So go ahead and tug on the ribbon. While you do, we will brew another needed cup of stimulation and prepare for another busy day. We know you can relate - meetings and deadlines await. Here are some interesting items to get you started. Have a great day... Genzyme Recalls Leukemia Drug Made At Ben Venue Plant (Bloomberg News) Hospitals Toss Scarce Drugs Due To Rules (MSNBC) NICE To Allergan: More Evidence Needed For Botox For Migraines (Bloomberg News) Sandoz Buys German Rights To Apricus Sex Drug (Reuters) Reed Elsevier Adds AstraZeneca CEO David Brennan As A Director (MarketWatch) GlaxoSmithKline Faces Opposition In Scotland To Wind Turbines (The Courier) FDA OKs GenProbe Test For Prostate Cancer Risk (Xconomy) Pfizer Claims $960M In Damages From Sun Pharma Over Protonix Patent (Economic Times) Merck Creates Joint Venture In Brazil (Associated Press) Harvard AIDS Coalition Protests Merck HIV Drug Pricing (Harvard Crimson) Novartis Boosts Investment In Taiwan (CENS) EDITOR'S NOTE: Please check this post for updates throughout the morning

A Biotech CEO's Three-Point Plan For Cutting Health Costs
Thu, 16 Feb 2012 12:37:33 GMT - Forbes.com
This post was written by Francois Nader, MD, a pharmaceutical industry veteran and President and Chief Executive of NPS Pharmaceuticals.

'Huge' market opportunity for European biosimilars - report
Thu, 16 Feb 2012 10:45:00 GMT - Kevin Grogan
'Huge' market opportunity for European biosimilars - report

UCB's Cimzia effective for psoriatic arthritis
Thu, 16 Feb 2012 09:54:00 GMT - Kevin Grogan
UCB's Cimzia effective for psoriatic arthritis

Ockham gets scale and depth with Nexus Oncology acquisition
Thu, 16 Feb 2012 09:01:00 GMT - Peter Mansell
Ockham gets scale and depth with Nexus Oncology acquisition

What's the social cost of making it harder to get Sudafed? - Boing Boing
Thu, 16 Feb 2012 03:33:00 GMT - insider
via boingboing.net Sudafed at $100 a pack! Now there's an idea! Posted via email from Jack's posterous

What's Causing a Shortage of Pediatric Cancer Drugs? | PBS NewsHour
Thu, 16 Feb 2012 03:15:00 GMT - insider
via pbs.org While more than 250 drugs were declared in short supply in the U.S. this past year, the latest worries centered on one called Methotrexate, considered essential for children battling leukemia. Ray Suarez discusses the problem and latest developments with Dr. Peter Adamson of The Children's Hospital of Philadelphia. Posted via email from Jack's posterous

BBC News - Not enough evidence for Botox migraine jab, says NICE
Thu, 16 Feb 2012 03:11:00 GMT - insider
he anti-wrinkle drug Botox is unlikely to be recommended for the treatment of chronic migraines on the NHS in England and Wales, the medicines watchdog said. The National Institute for Health and Clinical Excellence (NICE) has published draft guidelines saying there is insufficient evidence. It wants the manufacturer, Allergan, to provide better data before making a final decision in June. via bbc.co.uk Posted via email from Jack's posterous

Final Glance: Biotechnology companies
Wed, 15 Feb 2012 23:03:47 GMT

Avanir Pharmaceuticals: Nuedexta's First Birthday - Wiping Away The Tears
Wed, 15 Feb 2012 20:24:44 GMT

Reiterating Genomic at Neutral
Wed, 15 Feb 2012 19:45:23 GMT

With New Management, Teva Seeks To Reclaim Past Glories
Wed, 15 Feb 2012 18:53:49 GMT

Midday Glance: Biotechnology companies
Wed, 15 Feb 2012 18:21:47 GMT

OSC Joins Probe Over FDA Employee Whistleblowers
Wed, 15 Feb 2012 17:52:24 GMT - Ed Silverman
The probe into the sensational charges that the FDA secretly monitored several former and current employees, and then harassed and dismissed some of them, has now widened. The Office of Special Counsel, which is an independent federal investigative and prosecutorial agency, is also investigating. This follows a probe opened by the House Committee on Government Oversight and Reform (see here).

Maybe It's Time for Drug Companies to Drop TV Ads - Forbes
Wed, 15 Feb 2012 17:22:00 GMT - insider
via forbes.com If the pharmaceutical industry is really concerned about being better valued by the public, it might do well to drop TV ads completely. However well-intended they are, the negatives have always outweighed the benefits. If the members of the Pharmaceutical Research and Manufacturers Association agreed to halt TV ads, my guess is that the public's response would be overwhelmingly positive. My sense is that they wouldn't miss the commercials either. By John LaMattina Posted via email from Jack's posterous

Where Have All The Unreported Clinical Trials Gone?
Wed, 15 Feb 2012 17:11:57 GMT - Ed Silverman
Last month, a series of studies published in BMJ reported various problems with clinical trial data. More specifically, there is a lot that goes unpublished. Although the Food and Drug Administration Amendments Act requires mandatory reporting of summary clinical trial results within one year of completion on ClinicalTrials.gov, one BMJ paper found that only 22 percent adhered to the mandate (back story).

How secure are labs handling world's deadliest pathogens?
Wed, 15 Feb 2012 16:53:57 GMT
NEW YORK/CHICAGO (Reuters) - To reach his office in Galveston National Laboratory, where scientists study deadly pathogens such as the Ebola and Marburg viruses, director James Le Duc swipes his key card at the building's single entrance, which is guarded 24/7 by Texas state police.

The Lipitor Limbo: How Low Will It Go?
Wed, 15 Feb 2012 16:27:45 GMT - Ed Silverman
Before the recent arrival of a generic version of Lipitor, Pfizer undertook various gambits in hopes of wringing as much revenue as possible from its best-selling cholesterol pill. These tactics included offering a low-cost, co-pay card to consumers and providing discounts to health plans and pharmacy benefit managers (read here).


Hits and Misses

BioSante wins FDA nod for testosterone gel
BioSante Pharmaceuticals has won FDA approval for Bio-T-Gel, a testosterone gel for the treatment of male hypogonadism or low testosterone levels.

Valeant receives approval for secondary supplier of Methoxsalen
Valeant Pharmaceuticals has announced the FDA approval of an additional manufacturer of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis.

Gen-Probe receives FDA approval for PROGENSA PCA3 assay
Gen-Probe has received FDA approval for PROGENSA Prostate Cancer gene 3 (PCA3) assay, a urine-based molecular test to help determine need for repeat prostate biopsies.

CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
Thu, 16 Feb 2012 13:00:00 GMT
KING OF PRUSSIA, Pa., Feb. 16, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin...

Biosante Soars Following Drug Approval From FDA
Thu, 16 Feb 2012 12:51:40 GMT
From Associated Press (February 15, 2012) NEW YORK -- Shares of BioSante Pharmaceuticals Inc. surged Thursday after regulators approved a testosterone gel that will be marketed by its partner Teva Pharmaceutical Industries...

China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine
Wed, 15 Feb 2012 23:00:00 GMT
[Business Wire] - Affymetrix, Inc. today announced that its GeneChip® System 3000Dx v.2 has been approved by China's State Food and Drug Administration for in vitro diagnostic use.

Amylin's Bydureon Launches in the US
Wed, 15 Feb 2012 21:05:23 GMT

Children's Hospital of Michigan Cardiovascular Surgeon Testifies on Berlin Heart, now Approved by the FDA
Wed, 15 Feb 2012 19:09:00 GMT
DETROIT, Feb. 15, 2012 /PRNewswire-USNewswire/ -- Few hospitals have as much experience with the Berlin Heart as DMC Children's Hospital of Michigan. This is why the U.S. Food and Drug Administration (FDA) was eager to hear testimony from Henry L. Walters III, MD, chief of cardiovascular...


Deals and Dollars

ARIAD receives US patent for ponatinib pan-BCR-ABL inhibitor
ARIAD Pharmaceuticals has received a US patent which covers composition-of-matter patent protection for ponatinib, a pan-BCR-ABL inhibitor, through 22 December 2026.

Evotek, IR Pharma enter drug discovery alliance
Evotec and IR Pharma have signed an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of respiratory diseases.

Arno enters into licensing agreement with Invivis
Arno Therapeutics has entered into a worldwide licensing agreement with Invivis Pharmaceuticals to develop onapristone, an anti-progestin hormone blocker having considerable anti-tumor activity in breast cancer.

Asymchem invests in Dunhua manufacturing facility
Asymchem Laboratories (Tianjin) has launched new large scale manufacturing facility, operating under the name Jilin Asymchem Laboratories, located in Dunhua, PR China.

Merck, Supera Farma partner to commercialize generics in Brazil
Merck has established a new joint venture (JV) with Supera Farma Laboratorios to commercialize pharmaceutical and branded generic products in Brazil.

Evotek, IR Pharma enter drug discovery alliance
Evotec and IR Pharma have signed an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of respiratory diseases.

Apollo Medical Holdings, Inc. Appoints Edward "Ted" Schreck as Chairman of Its Board of Directors
Thu, 16 Feb 2012 14:00:00 GMT
GLENDALE, Calif., Feb. 16, 2012 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed") (OTC-AMEH.PK), a leading provider of hospitalist, critical care and multi-disciplinary care management services to the healthcare community, today announced the appointment of Edward "Ted"...

Cardium Announces Closing of $5.0 Million Equity Financing
Thu, 16 Feb 2012 14:00:00 GMT
SAN DIEGO, Feb. 16, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed the previously announced sale of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before...

Protalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock
Thu, 16 Feb 2012 13:40:00 GMT
CARMIEL, Israel, Feb. 16, 2012 (GLOBE NEWSWIRE) -- BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX), announced today the pricing of its previously announced underwritten public offering of 4.5 million shares of its common stock at a price to the public of $5.25 per share. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 675,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to settle and close on February 22, 2012, subject to customary closing conditions. Jefferies & Company, Inc. is acting as the sole book-running manager and each of Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. The Company expects to use the net proceeds from the sale of the shares primarily to fund clinical trials for the Company's product candidates, to fund the Company's research and development activities, to enhance the Company's manufacturing capacity, for working capital and general corporate purposes.

Biotonix (2010) Inc.: Biotonix Announces Private Placement Without Broker
Thu, 16 Feb 2012 13:34:00 GMT
BROSSARD, QUEBEC (MARKET WIRE) Biotonix (2010) Inc. (TSX VENTURE: BTX) ("Biotonix"), a company offering innovative postural health solutions, announces that it proposes to issue, by way of a private placement financing without broker to qualified investors, up to 4,000,000 units at $0.075 CAD per unit for a maximum amount of CAD $300,000.

Emdeon Announces Clinical Services Agreement with ICA, Educational Sessions During HIMSS12
Thu, 16 Feb 2012 13:30:00 GMT
NASHVILLE, Tenn., Feb. 16, 2012 /PRNewswire/ -- Emdeon Inc., a leading provider of revenue and payment cycle management and clinical information exchange solutions, today announced a clinical services agreement with Informatics Corporation of America (ICA) to help empower physician...

Novelos Therapeutics to Begin Trading on OTCQX
Thu, 16 Feb 2012 13:30:00 GMT
MADISON, Wis., Feb. 16, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, announced that today its common stock will begin trading on OTCQX, the top tier of the OTC market designated...

Xenogenics Received Rights to Polyanhydride Compounds Drug Delivery Patent
Thu, 16 Feb 2012 13:30:00 GMT
WOONSOCKET, R.I., Feb. 16, 2012 /PRNewswire/ -- Xenogenics Corporation, a subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has exclusive license rights to a polyanhydride compounds drug delivery patent recently granted in Canada. The patent was granted to...

CryoLife Reports Record Quarterly Revenues in Fourth Quarter of 2011
Thu, 16 Feb 2012 13:04:00 GMT
ATLANTA, Feb. 16, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2011. Revenues for the fourth quarter increased 4...

Amarin Corporation Appoints Dr. Steven Ketchum to Head Research and Development and Announces Inducement Grant Under NASDAQ Rule 5635(c)(4)
Thu, 16 Feb 2012 13:00:00 GMT
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Steven Ketchum, Ph.D., has been appointed President of Research and Development, Senior Vice President, effective February 16, 2012. Dr. Ketchum will be responsible for Amarin's drug discovery, preclinical and clinical development program and regulatory and medical affairs activities, including the ongoing development and regulatory review support for Amarin's lead product candidate, AMR101.

Amedica Corporation Completes $30 MM Financing to Expand Market Share of Proprietary Silicon Nitride Ceramic
Thu, 16 Feb 2012 13:00:00 GMT
SALT LAKE CITY, Feb. 16, 2012 /PRNewswire/ -- Amedica Corporation, a spinal and reconstructive implant manufacturer focused on its medical grade silicon nitride ceramic material, today announced the completion of its $30 million Senior Secured Subordinated Convertible Notes...

Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
Thu, 16 Feb 2012 13:00:00 GMT
EMERYVILLE, Calif., Feb.16, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that it will host a conference call on Tuesday,...

Complete Genomics Launches Genomic Discovery Software Partners Program
Thu, 16 Feb 2012 13:00:00 GMT
MOUNTAIN VIEW, Calif., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Complete Genomics Inc. (Nasdaq:GNOM), the whole human genome sequencing company, today introduced its Genomic Discovery Software Partners Program. Ingenuity(r) Systems, Golden Helix and DNAnexus have been chosen as initial partners because they have offerings that complement the information supplied with Complete Genomics' sequencing service and can expedite the genetic research of its customers.

Cubist Pharmaceuticals Appoints Alison Lawton to Board of Directors
Thu, 16 Feb 2012 13:00:00 GMT
[Business Wire] - Cubist Pharmaceuticals, Inc. today announced the appointment of Alison Lawton to its Board of Directors. Ms. Lawton is currently Senior Vice President, General Manager Biosurgery, at Genzyme Corporation .

Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2011 Financial Results and Pipeline Update
Thu, 16 Feb 2012 13:00:00 GMT
CAMBRIDGE, Mass., Feb. 16, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that it will report its financial results for the fourth quarter and year end 2011 on Thursday, February 23, 2012 after the U.S. financial markets close. Idenix management...

Nanosphere Announces Fourth Quarter and Full Year 2011 Results
Thu, 16 Feb 2012 13:00:00 GMT
NORTHBROOK, Ill., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the fourth quarter and full year ended December 31, 2011.

Omnicell Will Demonstrate Medication Automation Interoperability at HIMSS 2012
Thu, 16 Feb 2012 13:00:00 GMT
MOUNTAIN VIEW, Calif., Feb. 16, 2012 /PRNewswire/ -- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, will showcase its interoperable Modular EHR certified G4 platform at the 2012...

Pathfinder to Present at New York Stem Cell Summit
Thu, 16 Feb 2012 13:00:00 GMT
CAMBRIDGE, Mass., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, will present at the 7th Annual New York Stem Cell Summit being held on Tuesday, February 21, 2012.

Sagent Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Thu, 16 Feb 2012 13:00:00 GMT
SCHAUMBURG, Ill., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced financial results for the quarter and fiscal year ended December 31, 2011.

Chelsea Therapeutics to Present at Leerink Swann 2012 Global Healthcare Conference
Thu, 16 Feb 2012 12:30:00 GMT
CHARLOTTE, N.C., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced Dr. Simon Pedder, president and CEO, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference at 2:30 PM ET on Thursday, February 16, 2012 at the Waldorf Astoria Hotel in New York.

PDL BioPharma to Announce Fourth Quarter and Full Year 2011 Financial Results on February 23, 2012
Thu, 16 Feb 2012 12:00:00 GMT
INCLINE VILLAGE, Nev., Feb. 16, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year financial results for the period ended December 31, 2011 on Thursday, February 23, 2012 after market...

Trius Announces Issuance of Tedizolid Patent in China
Thu, 16 Feb 2012 12:00:00 GMT
SAN DIEGO, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic of China (PRC) that protects the composition of matter of the Company's Phase 3 investigational drug, tedizolid phosphate, through 2024. In addition to the issuance in China, patents for tedizolid phosphate have also issued in other jurisdictions including Australia, Canada, Europe, India, Japan, Mexico, Russia and the United States.

Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2011 Financial Results
Thu, 16 Feb 2012 11:48:00 GMT
DUBLIN, Ireland, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2011 on Monday, March 5, 2012. The Company has scheduled a conference call for that same day, Monday, March 5, 2012 at 11:00am EST (4:00pm GMT) to discuss the results of the quarter.

Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
Thu, 16 Feb 2012 11:30:00 GMT
ANAHEIM, Calif., Feb. 16, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Scott M. Whitcup, M.D., 52, to its Board of Directors. Dr. Whitcup is currently Executive Vice President, Research & Development and...

ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Thu, 16 Feb 2012 11:10:02 GMT

OPKO Health, Inc. Invests in ChromaDex® Corp.
Thu, 16 Feb 2012 11:00:00 GMT
MIAMI & IRVINE, Calif., Feb. 16, 2012 /PRNewswire/ -- OPKO Health, Inc. and ChromaDex Corporation (OTCBB: CDXC) announced today they have entered into a strategic alliance pursuant to which ChromaDex has licensed to OPKO all of its new product offerings and health care...

Merck & Co sets up Brazilian joint venture
Thu, 16 Feb 2012 10:00:00 GMT - Kevin Grogan
Merck & Co sets up Brazilian joint venture

ARIAD Pharmaceuticals, Inc. Earnings Call scheduled for Tue, Feb 28
Thu, 16 Feb 2012 09:36:33 GMT

Evotec and IR Pharma Establish Drug Discovery Alliance in the Field of Respiratory
Thu, 16 Feb 2012 06:38:00 GMT
HAMBURG, Germany, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.

Sanofi CEO Viehbacher: Biotech R&D returning 70 cents on the dollar
Thu, 16 Feb 2012 04:03:24 GMT - Business Journal
The CED Life Science Conference kicked off Wednesday with a keynote address by Sanofi CEO Christopher Viehbacher.

Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
Wed, 15 Feb 2012 22:49:00 GMT
[Business Wire] - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 1,125,000 shares at a public offering price of $10.75 per share.

Merck Establishes Joint Venture with Supera Farma
Wed, 15 Feb 2012 22:00:00 GMT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced the formation of a new joint venture (JV) with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company co-owned by Cristália and Eurofarma.

ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, 15 Feb 2012 21:31:47 GMT

Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
Wed, 15 Feb 2012 21:15:00 GMT
CARMIEL, Israel, Feb. 15, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX) announced today that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for the offering and each of Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotment, if any.

Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
Wed, 15 Feb 2012 21:05:00 GMT
SAN DIEGO, Feb. 15, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the completion of an underwritten public offering of 7,820,000 shares of its common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment...

Exelixis Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares
Wed, 15 Feb 2012 21:01:00 GMT
[Business Wire] - Exelixis, Inc. today announced the completion of its underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares.

Centene Corporation to Present at Citi 2012 Healthcare Conference
Wed, 15 Feb 2012 21:00:00 GMT
ST. LOUIS, Feb. 15, 2012 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced it will present at the 2012 Citi Global Healthcare Conference, to be held February 27-29, 2012, at the Waldorf=Astoria in New York City. Centene's presentation is scheduled for Tuesday, Feb....

Incyte Corporation's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, 15 Feb 2012 20:34:01 GMT
[at Seeking Alpha] - Incyte Corporation's CEO Discusses Q4 2011 Results - Earnings Call Transcript

IsZo Capital Writes to Special Committee of Taro Pharmaceutical Demanding the Immediate Rejection of Sun's Buyout Offer
Wed, 15 Feb 2012 20:24:25 GMT
NEW YORK, Feb. 15, 2012 /PRNewswire/ -- IsZo Capital LP, one of the largest minority shareholders of Taro Pharmaceutical Industries Ltd. (OTC: TAROF), announced today that it delivered the following letter to the Special Committee of the...

Alnylam to lay off 52 on March 23
Wed, 15 Feb 2012 20:06:24 GMT

Ariad wins key patent for leukemia drug
Wed, 15 Feb 2012 19:54:06 GMT - Boston.com
Details of a drug called ponatinib, which treats a form of leukemia, was diplayed on a computer screen at Ariad Pharmaceuticals.

FTC ends review of Amgen's purchase of Micromet
Wed, 15 Feb 2012 19:27:21 GMT

IsZo Capital Writes to Special Committee of Taro Pharmaceutical Demanding the Immediate Rejection of Sun's Buyout Offer
Wed, 15 Feb 2012 19:08:00 GMT
NEW YORK, Feb. 15, 2012 /PRNewswire/ -- IsZo Capital LP, one of the largest minority shareholders of Taro Pharmaceutical Industries Ltd. (OTC: TAROF), announced today that it delivered the following letter to the Special Committee of the Board of Directors of Taro demanding that...

Alnylam climbs 16% on stock offer pricing
Wed, 15 Feb 2012 19:06:41 GMT

Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive German Collaboration for Vitaros(R) for Erectile Dysfunction
Wed, 15 Feb 2012 17:36:00 GMT
SAN DIEGO, Feb. 15, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that its wholly-owned subsidiary NexMed(USA), Inc. has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to market Apricus Bio's Vitaros(r) drug for the treatment of erectile dysfunction.

Bionor Rises Most in 15 Months on AIDS Drug Study: Oslo Mover
Wed, 15 Feb 2012 17:21:23 GMT

Ablynx: Ablynx Will Announce Full Year Results for 2011 With Webcast
Wed, 15 Feb 2012 17:18:00 GMT
GHENT, BELGIUM (MARKET WIRE)


Regulatory Submissions

FDA accepts Pfizer tafamidis meglumine new drug application
The US Food and Drug Administration (FDA) has accepted Pfizer's new drug application (NDA) for tafamidis meglumine, an oral therapy for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP).

BioSyent Inc.: BioSyent Named to the TSX Venture Top 50(R) Ranking
Wed, 15 Feb 2012 23:28:00 GMT
MISSISSAUGA, ONTARIO (MARKET WIRE) BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announced today that it has been named as one of the 2012 TSX Venture Top 50 companies.


Clinical Research and Trials

CompuGroup releases new cloud-based lab connectivity software
CompuGroup Medical US has introduced LabNexus, a new software solution to assist hospital and reference labs with their outreach programs.

IRIC uses Roche xCELLigence SP Instrument in drug-induced cellular activity study
The Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal in Quebec, Canada, has used the Roche xCELLigence SP Instrument to measure changes in cell response following ligand stimulation.

AddBIO: Clinical Results - Implants With Bisphosphonate Show Improved Stability
Thu, 16 Feb 2012 14:00:00 GMT
STOCKHOLM, February 16, 2012 /PRNewswire/ -- AddBIO AB, a subsidiary of Accelerator Nordic AB, has developed Zolidd®, a proprietary bioactive nanolayer for orthopedic and dental implants that releases bisphosphonate, a bone strengthening drug. A randomized clinical trial, conducted...

Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis
Thu, 16 Feb 2012 13:00:00 GMT
LA JOLLA, Calif., Feb. 16, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the...

Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
Thu, 16 Feb 2012 12:30:00 GMT
EXTON, Pa., Feb. 16, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that data from the pivotal study for their orphan drug Plenadren® (hydrocortisone, modified release tablet) were published in the Journal of Clinical Endocrinology and Metabolism...

Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Thu, 16 Feb 2012 12:00:00 GMT
LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the...

BiondVax's Universal Flu Vaccine Improves Existing Flu Vaccines in Elderly. In a Second Phase II Trial, the Vaccine Proves Safe and Activates Immunity to Flu
Thu, 16 Feb 2012 11:47:00 GMT
NES ZIONA, Israel, February 16, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) today announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu...

CROMSOURCE accesses Phase I capabilities in Verona
Thu, 16 Feb 2012 09:00:00 GMT - Peter Mansell
CROMSOURCE accesses Phase I capabilities in Verona

Moffitt Center system matches trial drugs to tumour profiles
Thu, 16 Feb 2012 08:59:00 GMT - Peter Mansell
Moffitt Center system matches trial drugs to tumour profiles

Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
Wed, 15 Feb 2012 21:02:00 GMT
MINNEAPOLIS, Feb. 15, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the first enrollment of patients in the CONFIDeNT clinical study in the...

Ritter Pharmaceuticals, Inc.: Ritter Pharmaceuticals' Abstract on RP-G28's Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012
Wed, 15 Feb 2012 19:56:00 GMT
LOS ANGELES, CA (MARKET WIRE) Ritter Pharmaceuticals, Inc. has announced today that the abstract summarizing results from its Phase 2 study of RP-G28, a first-in-class treatment for lactose intolerance, was chosen for oral presentation at the annual international Digestive Disease Week (DDW) 2012(R), considered the largest meeting in the world for physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Rare mutations tied to breast, pancreatic cancers: study
Wed, 15 Feb 2012 19:28:16 GMT
NEW YORK (Reuters Health) - Mutations in genes that fix mismatched DNA may put people at extra risk for breast cancer and pancreatic cancer, in addition to their well-known ties to colon and endometrial cancers, a new report suggests.


The Rest of Today´s News

Health Management hospitals to deploy McKesson pharmacy automation solutions
Health Management Associates has signed an exclusive three-year technology agreement with McKesson to implement McKesson's complete suite of pharmacy automation solutions to standardize systems and procedures across hospital sites.

AFC continues investing in quality systems
AMPAC Fine Chemicals (AFC), a wholly owned subsidiary of American Pacific, has joined Rx-360 as an active member.

Evotek, IR Pharma enter drug discovery alliance
Evotec and IR Pharma have signed an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of respiratory diseases.

Stemming the tide of overtreatment in U.S. healthcare
Thu, 16 Feb 2012 14:13:52 GMT
CHICAGO (Reuters) - A leading group of U.S. doctors is trying to tackle the costly problem of excessive medical testing, hoping to avoid more government intervention in how they practice.

Singer Jon Secada Joins Merck and American Liver Foundation's 'Tune In to Hep C' Public Awareness Campaign
Thu, 16 Feb 2012 14:00:00 GMT
MIAMI, Feb. 16, 2012 /PRNewswire/ -- Merck (NYSE: MRK) (known as MSD outside the United States and Canada) today announced that three-time GRAMMY® award-winning Cuban-American recording artist and songwriter Jon Secada is adding his voice to the Tune In to Hep C public health...

ZoomMed inc.: ZoomMed Signs a 1M$ Software Development Agreement and Creates a Partnership with Sharpe Medical Consulting to Build and Commercialize an EMR for all Behavioral Health Providers
Thu, 16 Feb 2012 13:39:00 GMT
MONTREAL, QUEBEC (MARKET WIRE) ZoomMed Inc. (TSX VENTURE: ZMD), is proud to announce the signature of a 1M$ software development agreement and the creation of a partnership with Sharpe Medical Consulting, based in Washington DC, to bring together their resources to build and commercialize, throughout North America, an EMR (Electronic Medical Record) for all behavioral health providers.

Varian Medical Systems to Equip New Proton Treatment Center in Russia
Thu, 16 Feb 2012 13:30:00 GMT
PALO ALTO, Calif., Feb. 16, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has booked an order to equip a new two-room proton therapy center at the PTC St. Petersburg Center of Nuclear Medicine of the International Institute of Biological Systems in...

OnSiteRx® Launches First for Arizona: Automated Drug Dispensing in Nursing Home
Thu, 16 Feb 2012 13:25:00 GMT
DALLAS and FORT WORTH, Texas, Feb. 16, 2012 /PRNewswire/ -- OnSiteRx®, Inc. (http://www.onsiterx.com), parent organization for OnSiteRx® of Phoenix, LLC, in partnership with Covenant Health Network, announces today that they have successfully implemented the first automated...

FDA approves BioSante/Teva testosterone gel
Thu, 16 Feb 2012 11:29:00 GMT - Kevin Grogan
FDA approves BioSante/Teva testosterone gel

Counterfeit Avastin seized in the US
Thu, 16 Feb 2012 10:00:00 GMT - Selina McKee
Counterfeit Avastin seized in the US

ResearchMoz: Vaccine Production Market (Trends, Techniques, Key Players, Spending Estimates and Forecasts)
Thu, 16 Feb 2012 09:30:00 GMT
ALBANY, New York, February 16, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports DatabaseVaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts) The considerable revenue growth in the vaccine market over the past ten years suggests the amount of...

GoodRx™ Brings Price Transparency to Prescription Drugs
Thu, 16 Feb 2012 08:00:00 GMT
SANTA MONICA, Calif., Feb. 16, 2012 /PRNewswire/ -- GoodRx today announced that it has created an innovative prescription drug price comparison technology that provides consumers with accurate drug prices from virtually every U.S. pharmacy. GoodRx, available as both a website and free...

Video games lead to new paths to treat cancer
Thu, 16 Feb 2012 08:00:00 GMT
In a research lab at Wake Forest University, biophysicist and computer scientist Samuel Cho uses graphics processing units (GPUs), the technology that makes videogame images so realistic, to simulate the inner workings of human cells.

Safer than Smoking? Electronic Cigarette Explodes in Man's Mouth | Healthland
Thu, 16 Feb 2012 07:12:00 GMT - insider
via healthland.time.com Posted via email from Jack's posterous

Fakes Infiltrate Injectable Drugs
Thu, 16 Feb 2012 01:03:32 GMT

Doctors scour drug supplies after fake Avastin found
Thu, 16 Feb 2012 00:40:47 GMT
NEW YORK (Reuters) - A U.S. distributor of phony vials of the widely-used cancer drug Avastin aroused suspicion at doctor's offices as early as July, well before health regulators issued their own warning and sparked new alarm over counterfeit medicines.

InPlay: Affymetrix reports that China clears its first microarray platform for in vitro diagnostics to accelerate personalized medicine
Wed, 15 Feb 2012 23:12:46 GMT

New National Study Shows Integrative Medicine Commonly Used to Treat Chronic Health Conditions
Wed, 15 Feb 2012 22:35:00 GMT
MINNEAPOLIS, Feb. 15, 2012 /PRNewswire-USNewswire/ -- Seventy-five percent of integrative medicine centers included in a new study about integrative practice reported success treating chronic pain. More than half of centers reported successfully using integrative medicine to treat...

Integrative Medicine Use Up, but Outcomes Still Uncertain
Wed, 15 Feb 2012 22:06:21 GMT
In a survey of medical centers using integrative medicine, most reported success in treating chronic pain, gastrointestinal conditions, depression, anxiety, cancer symptoms, and chronic stress. Medscape Medical News

ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, 15 Feb 2012 21:31:47 GMT

How Fast You Walk and Your Grip in Middle Age May Predict Dementia, Stroke Risk
Wed, 15 Feb 2012 21:28:00 GMT
NEW ORLEANS, Feb. 15, 2012 /PRNewswire-USNewswire/ -- Simple tests such as walking speed and hand grip strength may help doctors determine how likely it is a middle-aged person will develop dementia or stroke. That's according to new research that was released today and will...

Insulet Corporation: Insulet Announces Global Agreement With LifeScan, Inc to Integrate Their OneTouch Blood Glucose Monitoring Technologies Into the OmniPod(R) Insulin Pump
Wed, 15 Feb 2012 21:15:00 GMT
BEDFORD, MA (MARKET WIRE) Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced it has signed a worldwide agreement with LifeScan, Inc. to integrate LifeScan's OneTouch(R) blood glucose monitoring technology into the OmniPod Personal Diabetes Manager ("PDM").

IsZo Capital Writes to Special Committee of Taro Pharmaceutical Demanding the Immediate Rejection of Sun's Buyout Offer
Wed, 15 Feb 2012 20:24:25 GMT
NEW YORK, Feb. 15, 2012 /PRNewswire/ -- IsZo Capital LP, one of the largest minority shareholders of Taro Pharmaceutical Industries Ltd. (OTC: TAROF), announced today that it delivered the following letter to the Special Committee of the...

Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
Wed, 15 Feb 2012 19:52:00 GMT
NEW YORK, Feb. 15, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) and the European Institute of Oncology (Instituto Europeo di Oncologia - IEO) introduced the Delcath Hepatic CHEMOSAT® Delivery System to media at a Feb. 15 press conference and discussed the...

Kids' language issues tied to moms' low vitamin D: study
Wed, 15 Feb 2012 19:23:01 GMT
NEW YORK (Reuters Health) - Mothers who had low vitamin D levels while they were pregnant are more likely to have a child with a language impairment than moms who had higher levels of the vitamin, according to a new study from Australia.

Asymchem Announces $20MM Investment in New Dunhua Commercial Manufacturing Facility
Wed, 15 Feb 2012 19:20:00 GMT
TIANJIN, China, Feb. 15, 2012 /PRNewswire/ -- Informex 2012 -- Asymchem Laboratories (Tianjin) Co. Ltd., a leading custom contract manufacturer serving the pharmaceutical industry, today announced the introduction of a brand new large scale manufacturing facility located...

PCI Synthesis: PCI Sponsors MassBio's Massachusetts CRO/CMO Symposium
Wed, 15 Feb 2012 19:16:00 GMT
NEWBURYPORT, MA (MARKET WIRE) PCI (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced its major sponsorship of the inaugural one-day Massachusetts Biotechnology Council (MassBio) CRO/CMO Symposium. The event will be held March 6 from 7:30am-5:30pm at Bentley University's Conference Center, LaCava 300, 75 Forest Street in Waltham.

Vote on 10-Month Medicare 'Doc Fix' May Come by Weekend
Wed, 15 Feb 2012 19:02:00 GMT
If the measure is passed, physicians could face another doc-fix drama in the lame-duck Congress following the November 6 general election. Medscape Medical News

Breakthrough Ultrasonic Acne Treatment Ready for Market Launch
Wed, 15 Feb 2012 19:00:00 GMT
BROOMALL, Pa., Feb. 15, 2012 /PRNewswire/ -- Transdermal Specialties, Inc (TSI) is a pioneer in Ultrasonic active patch delivery systems for the Drug and Skincare industries. The Company has completed clinical trials of its U-Wand™ Anti-Acne System. The U-Wand™ is an...

Cancer Would Decrease Sept. 11 Victim Payouts, Compensation Fund Head Says
Wed, 15 Feb 2012 18:15:41 GMT

AKC Canine Health Foundation: Breakthrough Canine Cancer Research Helps Dogs and Humans Live Longer, Healthier Lives
Wed, 15 Feb 2012 18:15:00 GMT
RALEIGH, NC (MARKET WIRE) An innovative cancer treatment process improving survival rates for dogs could soon take the phrase "man's best friend" to a whole new level, according to a research project funded by the AKC Canine Health Foundation (CHF).

Bishops plan big birth-control battle expansion
Wed, 15 Feb 2012 17:17:02 GMT
(Reuters) - Catholic bishops, energized by a battle over contraception funding, are planning an aggressive campaign to rally Americans against a long list of government measures which they say intrude on religious liberty.





The BioBlog    Find and Post Jobs    Industry Links

Comments?

© 2009 - 2012 by Feuerbach & Associates.  All rights reserved.

The Out Campaign: Scarlet Letter of Atheism